



MEDICAL PRECERTIFICATION REQUEST FORM

EOC ID:

Prolia (denosumab) injection 56

Phone: 1-866-461-7273 Fax back to: 1-888-447-3430

Humana manages the pharmacy drug benefit for your patient. Certain requests for precertification may require additional information from the prescriber. Please provide the following information and fax this form to the number listed above. Information left blank or illegible may delay the review process.

Form with two columns: Patient name and Prescriber name. Fields include Member/subscriber number, Patient date of birth, Group number, Address, City, state, ZIP, Fax, Office contact, Tax ID, Address, City, state, ZIP, Specialty/facility name, and Phone/NPI.

If the patient is a Medicare private-fee-for-service patient, which of the following applies?

I am giving notification. Yes ___ No ___

I am requesting an advanced coverage determination. Yes ___ No ___

[] By checking this box, I am requesting multiple drug reviews for this patient.

Expedited/exigent/urgent

[] By checking this box, I certify an expedited/exigent/urgent review is required. The patient has a health condition that may seriously jeopardize his/her life or ability to regain maximum function. (Please include explanation of exigency in the space below.)

Form with two columns: Drug name and strength, Directions/SIG, Quantity/units, Dose per infusion/injection, Number of infusions/injections, Number of cycles/frequency.

Is this a request for services already provided? Yes ___ No ___

If yes, please provide date of service: __/__/__

(Note: All reviews will be processed with generic equivalents for brand drugs whenever possible.)

Please attach pertinent medical history or information for this patient that may support approval and sign this form.

Form with four questions: Q1. Please provide diagnosis: *; Q2. Please provide J-Code, if applicable; Q3. Please provide ICD Diagnostic Codes; Q4. Is the drug requested part of a clinical trial? [] Yes [] No



MEDICAL PRECERTIFICATION REQUEST FORM

EOC ID:

Prolia (denosumab) injection 56

Phone: 1-866-461-7273 Fax back to: 1-888-447-3430

Patient Name:

Prescriber Name:

Q5. If yes, please provide the registration or identification number for the specific trial for which this drug is being studied (e.g. ClinicalTrials.gov Identifier: CT12345678): _____ *

Q6. Please indicate where the drug is being dispensed: *

- Pharmacy dispensed to patient
- Pharmacy shipped to prescriber
- Prescriber dispensed
- Other

Q7. If other, please specify: *

Q8. Please indicate if this request is a: *

- New start/ initial request
- Continuation/ Reauthorization request

Q9. For reauthorization requests do medical records demonstrate a stable or increasing BMD (bone mineral density) after a minimum trial of one year? *

- Yes
- No

Q10. Is the request for the treatment of one of the following: (Please mark all that apply) *

- Increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
- Increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
- Treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
- None of the above

Q11. Is the request for the treatment of osteoporosis for a patient at high risk for fracture (includes men and postmenopausal women)? *

- Yes
- No

Q12. Does the patient have a diagnosis of osteoporosis with a DXA hip (femoral neck) or spine T-score less than or equal to -2.5 within the past year? *

- Yes
- No

Q13. Does the patient have a history of a fracture of the spine or hip? *

- Yes
- No

Q14. Does the patient have a history of T-score between -1 and -2.5 with FRAX (WHO Fracture Risk Assessment Tool) major osteoporotic fracture probability greater than or equal to 20% or hip fracture probability is 3%? *



MEDICAL PRECERTIFICATION REQUEST FORM

EOC ID:

Prolia (denosumab) injection 56

Phone: 1-866-461-7273 Fax back to: 1-888-447-3430

Patient Name:	Prescriber Name:
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q15. Has the patient had a 12 month minimum trial (e.g. lack of desired improvement in BMD or recurring fractures) with Reclast (zoledronate)? *	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q16. Has the patient had an adverse reaction, intolerance, or contraindication to bisphosphonate(s)? *	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q17. Additional Comments: *	

Prescriber signature

Date

I declare under penalty of perjury under the laws of the United States of America that the information provided is true and correct. This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document. LC3035ALL1019 2019-11-22